Post Autologous Stem Cell Transplantation Complication Management in Case of Malignant Lymphoma Patients

Annamária Pakucs 1 , 2 , Erzsébet Lázár 1 , 2 , Judit Beáta Köpeczi 1 , Enikő Kakucs 1 , István Benedek Jr 1 , 2 , Marius Găzdac 1 , Eszter Mild 1 , 2 , Cezara Tudor 1 , 2  und István Benedek 1 , 2
  • 1 Clinic of Hematology and Bone Marrow Transplantation Unit, , Tîrgu Mureş, Romania
  • 2 University of Medicine and Pharmacy, , Tîrgu Mureş, Romania

Abstract

Introduction: Autologous hematopoietic stem cell transplantation (ASCT) represents a standard therapy in the management of hematologic malignancies such as malignant lymphomas and has used for approximately three decades. The aim of this study was to determine the occurring post-ASCT complications and their impact on the patients’ recovery for a better management.

Material and methods: An observational retrospective study was performed during a five-year period between 2012 and 2017, involving 58 classical Hodgkin lymphoma and 36 non-Hodgkin lymphoma patients, who underwent ASCT in the Bone Marrow Transplantation Unit of Tîrgu Mureş. The main analyzed complications were: infections, bleeding, hydroelectrolytic disorders, and hypoalbuminemia.

Results: After data analysis we found that 17 patients (18%) presented microbiologically confirmed infection, 10 patients (11%) presented clinically non-significant bleeding, 39 patients (42%) presented electrolyte disorders, and 33 patients (36%) presented hypoalbuminemia, obtaining a positive correlation between the rate of adverse events after ASCT with age (r = 0.9914, p = 0.0009) and the average hospitalization period (r = 1, p <0.00001).

Conclusions: The identification of adverse events and their correlation with the patients’ clinical outcome can lead to better patient management and a faster recovery after ASCT.

Falls das inline PDF nicht korrekt dargestellt ist, können Sie das PDF hier herunterladen.

  • 1. Hübel K, de la Rubbia J, Azar N, et al. Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective. Eur J Haematol. 2015;94:12-22.

  • 2. Benekou K, Montoto S. Role of stem cell transplant in lymphoma in the era of new drugs. Curr Opin Oncol. 2017;29:455-459.

  • 3. Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18:1076-1088.

  • 4. Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40000 transplants. Bone Marrow Transplant. 2016;51:786-792.

  • 5. Scheich S, Reinheimer C, Brandt C, et al: Clinical Impact of Colonization with Multidrug-Resistant Organisms on Outcome after Autologous Stem Cell Transplantation: A Retrospective Single-Center Study. Biol Blood Marrow Transplant. 2017;23:1455-1462.

  • 6. Calmels B, Lemarie C, Esterni B, et al. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. Transfusion. 2007;47:1268-1275.

  • 7. Jones JA, Qazilbash MH, Shih YC, et al. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer. 2008;112:1096-1105.

  • 8. Otrock ZK, Sempek DS, Carey S, et al. Adverse events of cryopreserved hematopoietic stem cell infusions in adults: a single-center observational study. Transfusion. 2017;57:1522-1526.

OPEN ACCESS

Zeitschrift + Hefte

Suche